Oyster Point Pharma’s nasal spray treatment for dry eye disease has met its primary endpoints in the phase 2 MYSTIC trial, CEO and President Jeffrey Nau, PhD, said at the J.P. Morgan Healthcare Conference.
OC-01 (varenicline) nasal spray is a selective nicotinic acetylcholine receptor agonist. The MYSTIC study evaluated the safety and efficacy of two doses (0.6 mg/mL and 1.2 mg/mL) of OC-01 in patients with dry eye. Subjects received twice-daily dosing of OC-01 over 84 days.
“When we look at the data over time, you see really consistent tear (Read more...)
Uncategorized